tradingkey.logo

Sarepta Says 51-Year-Old Male Patient Died In Early Stage Study Of SRP-9004

ReutersJul 18, 2025 2:17 PM

- Sarepta Therapeutics Inc SRPT.O:

  • SAREPTA THERAPEUTICS SAYS 51-YEAR-OLD MALE PATIENT DIED IN AN EARLY STAGE STUDY OF CO'S THERAPY SRP-9004 - STATEMENT

  • SAREPTA THERAPEUTICS SAYS PATIENT WAS THE LAST TO BE DOSED IN THE STUDY, AND DIED OF ACUTE LIVER FAILURE

  • SAREPTA THERAPEUTICS SAYS PRIORITIZED DISCLOSING TRIAL PATIENT DEATH TO CLINICIANS, REGULATORS IN ACCORDANCE WITH TRIAL GUIDELINES

  • SAREPTA THERAPEUTICS SAYS ACUTE LIVER FAILURE IS NOT A NEW SAFETY SIGNAL, OCCURRED IN A TRIAL FOR A PROGRAM THAT CO IS NOT MOVING FORWARD WITH

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI